Drug registration application for treatment of NSCLC patients by Beida Pharmaceuticals Ensatinib has been approved by the National Drug Administration
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, The NationalMedicines(http://Regulatory Authority has accepted the registration of drugs for patients with their statine nsatinib for patients with pre-conditioned metastatic lymphoma late-stage or metastatic non-small cell lung cancer (NSCLC) who have previously received treatment with keratininib or who are intolerant of kerendinibThere are currently three ALK inhibitors already on the market in China, namely Pfizer's Crizotinib, Novartis's Seritinib and Roche's Allotinibon the ensatinib hydrochloric acidNsatinib is a new, fully proprietary molecular entity compound developed by Beda Pharmaceuticals and holding subsidiarycompany(http://Xcovery Holdings, primarily for the treatment of ALK fusion mutation-positive non-small cell lung cancerin in vitro cytomeology, Nsatinib inhibited the growth capacity of ALK-positive lung cancer cell lines 10 times, and for the L1196M and C1156Y mutations that cause derottoni resistance, Nsatinib also showed strong inhibition activity, Ensatinib and Aellotinib, as the best-performing second-generation ALK inhibitors, the company has conducted a number of clinical studies on ostacid Ensatinib at home and abroad, including the first-line treatment of ALK-positive NSCLC patients in the global multicenter phase III clinicaltrial(http://has been completed into the group, the current clinical research is progressing smoothly
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
